COMPASS Pathways plc
COMPASS Pathways is a biotechnology company developing mental health treatments for people with serious conditions who are not helped by existing treatments. Its main product is investigational COMP360, a proprietary formulation of pharmaceutical-grade psilocybin. The company’s initial focus is treatment-resistant depression, and it is also developing COMP360 for post-traumatic stress disorder. Its clinical programs include Phase 3 trials for treatment-resistant depression and a Phase 2b/3 trial for post-traumatic stress disorder. COMPASS Pathways has also conducted development work in anorexia nervosa. COMPASS Pathways is developing COMP360 as a treatment delivered with healthcare professional support, including preparation, an administration session and follow-up. It retains global development and commercialization rights for the treatment. Its business is centered on researching and developing the investigational therapy, with potential commercialization subject to approval. COMPASS Pathways is headquartered in Cheshire, United Kingdom.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CMPS in the last 30 days.
See all $CMPS insider activity →The DEA plans to boost legal production of certain psychedelics in 2027 for medical and scientific research, according to a draft Federal Register notice. This move could impact companies involved in psychedelics research, such as Compass Pathways (CMPS).
Jefferies predicts Compass Pathways (CMPS) may gain FDA approval for its psilocybin-based depression drug COMP360 by early 2027, with a potential US launch and $31M revenue. The forecast is based on completed NDA submission, positive clinical data, and expedited review. The drug targets treatment-resistant depression, with potential benefits over JNJ's Spravato.
HC Wainwright & Co. reiterated a Buy rating for Compass Pathways (CMPS) with a $65 price target, implying a 654.9% upside from the Nov 6 close of $8.61.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning CMPS (COMPASS Pathways plc). Coverage has skewed bullish: 6 bullish, 1 neutral, and 2 bearish.
Recent CMPS coverage spans financial news, regulation and earnings.
Regulatory expansion could improve market outlook for Compass Pathways.
Potential approval could unlock a new market for psilocybin therapy, driving revenue growth.
Analyst upgrade and high price target may generate buying interest.
The downgrade suggests potential downside pressure on the stock.
The downward revision suggests reduced upside expectations.
AlphAI scores every news story that mentions CMPS with an AI model for sentiment and relevance, and aggregates insider trades from COMPASS Pathways plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
The DEA plans to boost legal production of certain psychedelics in 2027 for medical and scientific research, according to a draft Federal Register notice. This move could impact companies involved in psychedelics research, such as Compass Pathways (CMPS).
Jefferies predicts Compass Pathways (CMPS) may gain FDA approval for its psilocybin-based depression drug COMP360 by early 2027, with a potential US launch and $31M revenue. The forecast is based on completed NDA submission, positive clinical data, and expedited review. The drug targets treatment-resistant depression, with potential benefits over JNJ's Spravato.
HC Wainwright & Co. reiterated a Buy rating for Compass Pathways (CMPS) with a $65 price target, implying a 654.9% upside from the Nov 6 close of $8.61.
Wells Fargo kept Compass at Equal-Weight but reduced its price target to $9 from $10, a 10% cut. This implies a 2.4% downside from the Nov 5 close of $9.22. Other recent analyst targets for Compass range from $13 to $15.
Analysts' average price target for COMPASS Pathways ADS fell slightly from $23.35 to $23.18, with a range of $10 to $65. This implies a 176% upside from the Nov. 2 closing price. The consensus rating remains 'Buy' among 18 analysts.
Compass Pathways (CMPS) reported Q3 2026 results, nearing NDA submission for COMP360. Launch readiness is on track for H1 2027, subject to FDA approval. Phase 3 data supports COMP360's potential as a blockbuster treatment for TRD, with a strong cash position of $444M. The company will host a conference call on November 3.
BTIG reiterated a Buy rating and $25 price target for Compass Pathways (CMPS), citing completed trials and upcoming FDA action. The stock trades at $9.11, down 29% in a week. InvestingPro notes undervaluation, with analyst targets up to $65. The company reported a smaller-than-expected Q3 loss, $0.31 per share vs. $0.36 estimate.
Compass Pathways (CMPS) is nearing completion of its NDA submission for COMP360, a treatment for treatment-resistant depression (TRD), with a filing expected in two weeks. Positive Phase 3 trial data shows durability of effect up to one year. The company aims for a H1 2027 launch, subject to FDA approval. COMP360 is seen as a potential blockbuster with a large market opportunity. Compass also has a late-stage PTSD trial ongoing and a strong cash position into 2028.
Compass Pathways (CMPS) is developing COMP360, a psychedelic treatment for depression, with FDA approval potentially coming in early 2027. Phase 3 trials showed sustained symptom reduction in 40-45% of patients. The company expects to complete its FDA application by year-end. Analysts see 95% upside, with shares trading around $12 and an average target of $23.75.
Compass Pathways Plc, a pre-revenue biotech, reports Q3 results with focus on FDA approval for its psilocybin therapy, COMP360. Analysts expect a loss of 36 cents per share, improved from prior quarters. Shares are up from 52-week lows but below yearly highs. Analysts rate it a Strong Buy with a $23.75 price target. Investors await updates on FDA submission, commercial readiness, and cash burn ahead of a potential 2027 launch.
